-
In advanced prostate cancer with PSA levels >1000 ng/mL, sufficient PSA-A2M is present in circulation to produce enzymatic activity against circulating small peptide hormones.
-
The aim of the study was to examine treatment patterns/outcomes with abiraterone (abi)/enzalutamide (enza) throughout PSA progression and near the end of life...abiraterone (abi)/enzalutamide are frequently discontinued for PSA progression alone and continued at end of life . The clinical benefit of these practices warrants additional study.
-
The functional role of glycosylation in prostate-specific KLK3 could pave the way to a deeper understanding of their biology and to medical applications.
-
These results shed a light on the genetic background of Benign prostatic hyperplasia and associated lower urinary tract symptoms and its substantial influence on PSA levels.
-
Studies indicate that ghgh level of gamma-seminoprotein (gama-SM)/Prostate-Specific Antigen (PSA) could be detected in the blood [Review].
-
Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.
-
Men with mild to no lower urinary tract symptoms (LUTS) but increased baseline PSA are at increased risk of developing incident LUTS presumed due to benign prostatic hyperplasia
-
PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.
-
Differences in fPSA-recovery between all investigated assays were even more pronounced. When applying the tPSA cutoff of 3.1 mug/L recommended for WHO-calibrated assays, the use of higher calibrated assays may lead to unnecessary prostate biopsies. Conversely, if the historical threshold of 4 mug/L is applied when using WHO-calibrated assays, it could lead to falsely omitted prostate biopsies.
-
PSA was the only independent predictor of extensive lymph node invasion and could be an important preoperative factor for stratifying high-risk patients.
-
ue to the biocompatibility, multivalency, stability, and high structural homogeneity, the t-PSA-specific landscape phage demonstrates as a novel specific interface in biosensors.
-
Based on the target-induced catalytic hairpin assembly and bimetallic catalyst, the enzyme-free recycling amplification strategy for sensitive detection of prostate specific antigen (PSA) has been designed
-
The prepared biosensor can assay from 0 to 500ng/mL of prostate specific antigen (PSA) level within 2h with the detection limit of 1.18ng/mL by the measurement of resistance change. The resistance change was caused by site selective interaction between PSA and PSA-antigen with an inexpensive bench top digital multimeter (5 1/2 digits)
-
he superwettable f-PSA microchip can accurately detect human serum samples with excellent correlations with chemiluminescence immunoassay in the clinic, demonstrating its great potential as a sensitive and reliable sensing platform for biological analysis and clinical diagnosis.
-
The 12-week PSA response rate was 88% (22/25) and 22% (4/18), median time to PSA progression was 18.2 months [95% confidence interval (CI), 8.3 months-not reached) and 3.7 months (95% CI, 2.8-5.6 months), and median time on treatment 21 months (range, 2.6-37.5) and 4.9 months (range, 1.3-23.2), for the AAP-naive and post-AAP cohorts, respectively.
-
The results support that u-PSA provides useful information for predicting predicting biochemical recurrence after radical prostatectomy . This can be beneficial to avoid unnecessary adjuvant treatments or to start them earlier for selected patients
-
this meta-analysis suggests that PSA -158G/A polymorphism may be a protecting factor against BPH in Caucasian populations, but it may enhance the disease risk in Asians.
-
Developed risk assessment models for North Chinese patients with 4-50 ng/mL PSA to reduce unnecessary prostate biopsies and increase the detection rate of prostate cancer.
-
Data show positive associations of relative Gal-3 and relative PSA levels in prostate cancer patients, notably at early clinical time course.
-
Both the extent of comorbidity and the PSA doubling time should be taken into consideration when deciding on appropriate management and/or clinical trial eligibility at the time of PSA failure.
